Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide

Annals of Clinical Microbiology and Antimicrobials

Volumn 10, Issue , 2011, Pages

  Cao, Shanping ^a   Sun, Lun Quan ^b   Wang, Ming ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CIPROFLOXACIN; NU 3 [BUTYL PHOSPHATE 5 THYMIDINE 3 PHOSPHATE BUTYL]; NUCLEOTIDE DERIVATIVE; OXACILLIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; NUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIUM ISOLATE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; THERAPY EFFECT; WOUND INFECTION; ANIMAL; BACTERIAL INFECTION; BACTERIUM; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DNA REPLICATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NUCLEOTIDES; WOUND INFECTION;

EID: 78651362134     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-10-1     Document Type: Article

References (19)

1. Gould IM. Antimicrobials: an endangered species?. Int J Antimicrob Agents 2007, 30:383-4. 10.1016/j.ijantimicag.2007.07.008, 17825532.
2. Byarugaba DK. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 2004, 24:105-10. 10.1016/j.ijantimicag.2004.02.015, 15288307.
3. Okeke IN, Laxminarayan RZ, Bhutta A, Duse AG, Jenkins P, O'Brien TF, Pablos-Mendez A, Klugman KP. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005, 5:481-93. 10.1016/S1473-3099(05)70189-4, 16048717.
4. Bax RP. Antibiotic resistance: a view from the pharmaceutical industry. Clin Infect Dis 1997, 24(Suppl 1):S151-3.
5. Bax R, Mullan N, Verhoef J. The millennium bugs--the need for and development of new antibacterials. Int J Antimicrob Agents 2000, 16:51-9. 10.1016/S0924-8579(00)00189-8, 11185414.
6. Dale RM, Schnell G, Wong JP. Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004, 48:2918-23. 10.1128/AAC.48.8.2918-2923.2004, 478511, 15273101.
7. Sun J, Hu Y, Cao S, Zhang G, Sun LQ, Wang M. Evaluation of the Acute, Multiple-Dose Dermal and Genetic Toxicity of Nu-3, an Antimicrobial Agent. J Biomedicine Biotechnology 2010,
8. Clinical and Laboratory Standards Institute Methods for Determining Bactericidal Activity of Antimicrobial Agents. 1999, Approved Guideline M26-A CLSI, Wayne, PA, USA, Clinical and Laboratory Standards Institute.
9. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 2006, Approved Standard M7-A7 CLSI, Wayne, PA, USA, Clinical and Laboratory Standards Institute.
10. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. 2008, Eighteenth Informational Supplement M100-S18. Wayne, PA, USA: CLSI, Clinical and Laboratory Standards Institute.
11. Conley JH, Yang T, Wilson K, Blasetti V, Ninno D, Schnell G, Wong JP. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997, 41:1288-92. 163901, 9174185.
12. Gisby J, Bryant J. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 2000, 44:255-60. 10.1128/AAC.44.2.255-260.2000, 89667, 10639346.
13. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61:377-92. 232616, 9293187.
14. Novo DN, Perlmutter G, Hunt RH, Shapiro HM. Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry 1999, 35:55-63. 10.1002/(SICI)1097-0320(19990101)35:1<55::AID-CYTO8>3.0.CO;2-2, 10554181.
15. McRipley RJ, Whitney RR. Characterization and quantitation of experimental surgical-wound infections used to evaluate topical antibacterial agents. Antimicrob Agents Chemother 1976, 10:38-44. 429686, 984756.
16. Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc 2001, 6:170-4. 10.1046/j.0022-202x.2001.00043.x, 11924823.
17. Larson EL, Gomez-Duarte C, Lee LV, Della-Latta P, Kain DJ, Keswick BH. Microbial flora of hands of homemakers. Am J Infect Control 2003, 31:72-9. 10.1067/mic.2003.33, 12665739.
18. Miltenburger HG, Sachse G, Schliermann M. S-phase cell detection with a monoclonal antibody. Dev Biol Stand 1987, 66:91-9.
19. Plasek J, Sigler K. Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. J Photochem Photobiol B 1996, 33:101-2. 10.1016/1011-1344(96)07283-1, 8691353.